MET and non-small cell lung carcinoma: The MET exon 14 skipping mutation inhibitors capmatinib, tepotinib, and savolitinib have been proposed for the treatment of adult patients with metastatic NSCLC whose tumors harbor this mutation, irrespective of tumor histology.